Financials data is unavailable for this security.
View more
Year on year Haba Laboratories Inc was unable to grow net income despite reducing the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales). Net income shrank 199.30% from a loss of 707.87m to a larger loss of 2.12bn despite revenues that were relatively flat.
| Gross margin | 67.63% |
|---|---|
| Net profit margin | -14.60% |
| Operating margin | -11.32% |
| Return on assets | -13.37% |
|---|---|
| Return on equity | -19.22% |
| Return on investment | -17.19% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Haba Laboratories Inc fell by 858.65m. Cash Flow from Financing totalled 171.07m or 1.39% of revenues. In addition the company used 587.92m for operations while cash used for investing totalled 441.79m.
| Cash flow per share | -382.71 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2,205.39 |
|---|---|
| Tangible book value per share | 2,201.16 |
More ▼
Balance sheet in JPYView more
| Current ratio | 3.05 |
|---|---|
| Quick ratio | 1.77 |
| Total debt/total equity | 0.2735 |
|---|---|
| Total debt/total capital | 0.2148 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -199.30%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.27% |
|---|---|
| Div growth rate (5 year) | 0.00% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -117.50 |
More ▼
